Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab in Anti-TNF Naïve Active Psoriatic Arthritis (INSPIRE 2)
NCT04314531Phase 3Active, not recruiting
- Sponsor
- Sun Pharma
- Start
- Jul 2020
- Primary completion
- Jun 2025
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of tildrakizumab in psoriatic arthritis (PsA), sponsored by Sun Pharma. Primary endpoint: American College of Rheumatology 20% improvement at 24 weeks. Started Jul 2020; status: active, not recruiting.
02
Drugs
tildrakizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04314531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04314531.